Mark Hillman Hillman Capital Management
Mark Hillman is associated with Hillman Capital Management, a firm focused on fundamental equity research and long-term portfolio management. The firm’s public filings are followed by investors interested in actively managed, research-driven U.S. equity exposure. Hillman’s process emphasizes business analysis and valuation discipline rather than short-term trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veeva Systems
VEEV
|
+$2.31M |
| 2 |
Accenture
ACN
|
+$530K |
| 3 |
Salesforce
CRM
|
+$475K |
| 4 |
Conagra Brands
CAG
|
+$462K |
| 5 |
Adobe
ADBE
|
+$258K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
T. Rowe Price
TROW
|
+$2.28M |
| 2 |
CVS Health
CVS
|
+$1.07M |
| 3 |
Biogen
BIIB
|
+$1.06M |
| 4 |
TSMC
TSM
|
+$955K |
| 5 |
Oracle
ORCL
|
+$836K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.88% |
| 2 | Consumer Staples | 18.68% |
| 3 | Technology | 14.99% |
| 4 | Communication Services | 9.25% |
| 5 | Materials | 7.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CVS Health
CVS
$119B
| $5.74M | 4.15% |
55,475
-11,987
| -18% | -$1.07M |
|
|
2
Biogen
BIIB
$32B
| $5.18M | 3.75% |
23,993
-5,547
| -19% | -$1.06M |
|
3
DuPont de Nemours
DD
$18.7B
| $5.12M | 3.71% |
37,745
-1,555
| -4% | -$221K |
|
4
Warner Bros
WBD
$71.6B
| $5.07M | 3.67% |
189,986
-6,323
| -3% | -$171K |
|
5
Baxter International
BAX
$13.6B
| $5.03M | 3.64% |
236,032
-11,288
| -5% | -$210K |
|
6
International Flavors & Fragrances
IFF
$21.5B
| $4.98M | 3.61% |
62,875
-9,898
| -14% | -$737K |
|
7
GSK
GSK
$105B
| $4.84M | 3.51% |
92,383
-5,049
| -5% | -$267K |
|
8
CarMax
KMX
$8.82B
| $4.83M | 3.5% |
91,385
-17,796
| -16% | -$774K |
|
9
Boeing
BA
$169B
| $4.67M | 3.38% |
21,574
-752
| -3% | -$167K |
|
10
Zimmer Biomet
ZBH
$19.3B
| $4.64M | 3.36% |
53,943
-1,757
| -3% | -$154K |
|
11
Kraft Heinz
KHC
$30.3B
| $4.64M | 3.36% |
196,494
-4,646
| -2% | -$107K |
|
12
Brown-Forman Class B
BF.B
$13.1B
| $4.6M | 3.33% |
172,514
-3,923
| -2% | -$106K |
|
13
Pfizer
PFE
$160B
| $4.2M | 3.04% |
174,610
-13,327
| -7% | -$349K |
|
14
Estee Lauder
EL
$36.9B
| $3.97M | 2.87% |
50,226
-1,946
| -4% | -$157K |
|
|
FISV
15
Fiserv Inc
FISV
$28B
| $3.85M | 2.79% |
78,456
-2,272
| -3% | -$127K |
|
16
Microsoft
MSFT
$3.59T
| $3.84M | 2.78% |
10,296
-532
| -5% | -$215K |
|
17
Campbell Soup
CPB
$7.14B
| $3.59M | 2.6% |
161,043
-5,135
| -3% | -$108K |
|
|
18
Adobe
ADBE
$109B
| $3.54M | 2.57% |
17,288
+1,088
| +7% | +$258K |
|
19
iShares MSCI EAFE ETF
EFA
$80B
| $3.3M | 2.39% |
31,743
+889
| +3% | +$91.4K |
|
20
Nike
NKE
$60.5B
| $3.21M | 2.32% |
78,213
+307
| +0.4% | +$13.5K |
|
|
21
TSMC
TSM
$2.17T
| $2.68M | 1.94% |
5,608
-2,354
| -30% | -$955K |
|
22
Bristol-Myers Squibb
BMY
$137B
| $2.61M | 1.89% |
45,235
-7,867
| -15% | -$452K |
|
23
West Pharmaceutical
WST
$24.8B
| $2.55M | 1.85% |
7,106
-1,800
| -20% | -$550K |
|
24
US Bancorp
USB
$96.7B
| $2.49M | 1.8% |
41,252
-11,276
| -21% | -$632K |
|
|
25
Veeva Systems
VEEV
$40.3B
| $2.49M | 1.8% |
+14,008
| New | +$2.31M |
|
Similar funds
Mark Hillman's Q2 2026 Portfolio in Review
As of Q2 2026, Mark Hillman held 58 positions worth $138M, down 4.1% from $144M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Mark Hillman withdrew a net $10.4M in Q2 2026, closing 4 positions and reducing 36 holdings. Its most notable exit was GE Aerospace, an estimated $364K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 28% a quarter earlier, followed by Consumer Staples and Technology.
Against the trend, Mark Hillman opened a new position in Veeva Systems worth $2.49M.
- Mark Hillman's largest Q2 2026 buy was Veeva Systems: 14,008 shares worth $2.49M.
- Mark Hillman added most to Salesforce in Q2 2026, an estimated $475K increase.
- Mark Hillman's biggest Q2 2026 reduction was T. Rowe Price, cutting an estimated $2.28M.
- Mark Hillman fully exited GE Aerospace in Q2 2026, selling an estimated $364K.
- Mark Hillman's ten largest holdings make up 36% of its $138M portfolio in Q2 2026.
- Mark Hillman opened 2 new positions and closed 4 in Q2 2026.
- Mark Hillman's portfolio value fell 4.1% quarter-over-quarter to $138M.
Based on Hillman Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.